-
Surfshark Adds Real-Time Call Protection to iOS App in Version 5.3.0
-
Samsung Galaxy Buds Active Leak Reveals ANC, Ear-Hook Design and One UI 9.5 Integration
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Egypt and Syria Sign Agreement to Restore Direct Flights After 14-Year Hiatus
-
Professor Shahida Moosa Pioneers Medical Genomics in South Africa Amid Testing Shortages
-
Van Gogh’s ‘Châtaigniers en Fleurs’ Sets $285m Record at Sotheby’s
-
Texas Marijuana Decriminalization Faces Uncertain Future Under New Attorney General
-
Anthropic Sets Record $81.3 Billion IPO Valuing AI Firm at $1.5 Trillion
-
Early Black Friday Laptop Deals: MacBook Neo, IdeaPad Slim 5x, and Surface Laptop Prices Drop
-
eThekwini Faces R6.5bn Flood Claim from Toyota’s Insurer
-
2026 East Bay Nosh Awards Voting Opens for Food and Drink Favorites
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
BHG Financial Celebrates 25 Years of Innovation with Women in Technology Panel and Donates to Girls Who Code
-
Wildfire Season Is Over - The Legal Clock Is Not
-
Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up
-
APPA Launches 2026 Pet Industry Holiday Gift Guide, Backed by New Pet Gifting Data
-
United Bancorp, Inc. Increases its Fourth Quarter Cash Dividend Payment to $0.20 per Share, which Produces a Forward Yield of 5.4%
Trump signs order aimed at lowering drug prices
US President Donald Trump signed an executive order Tuesday aiming to lower crippling drug prices by giving states more leeway to bargain-hunt abroad and improving the process for price negotiations.
Americans face the highest prescription drug prices in the world, leaving many people to pay partially out of their own pockets despite already exorbitant insurance premiums.
"This (order) will provide meaningful relief to seniors and low income individuals who depend on insulin and many, many more," a White House official told reporters.
"Furthermore, it will foster a more competitive prescription drug market to ensure the prices being charged to patients and the government are more aligned with the value they provide, rather than some quirk in the way that the government pays for them."
The order directs the Food and Drug Administration (FDA), which regulates prescription and over-the-counter pharmaceuticals, to allow more states to import medicines directly from countries with lower prices.
The administration of Trump's predecessor Joe Biden approved Florida's application to import from Canada last year but no other states were given the green light for their own deals.
The order also tweaks the Inflation Reduction Act (IRA) passed under Biden, which allowed the Medicare health insurance plan for seniors to negotiate the prices of certain drugs for the first time.
The aim of the changes is to eliminate the difference between price negotiation rules for pills and those for injectable drugs -- a disparity that critics argue could harm investment in the orally-administered products.
Under the IRA, Medicare could negotiate on prices for "small molecule" drugs that patients swallow, such as ibuprofen, nine years after FDA approval.
"Large molecule" biologics such as gene-based therapies and hormonal regulators could only be subject to negotiations after 13 years.
The order did not specify how the disparity would be addressed.
Officials said the edict also did not make use of a "most favored nation" status that would force pharmaceutical companies to offer their lowest prices in America.
Biden's IRA reforms led to the costs of 10 key medicines being cut in landmark negotiations with pharmaceutical firms.
Days before leaving office, the Democrat announced a further 15 drugs for which the government would negotiate lower prices with pharmaceutical companies, with the resulting prices taking effect in 2027.
G.Stevens--AMWN